Novo Nordisk is engaged in a legal dispute with Hims & Hers Health over unauthorized versions of its popular drugs Wegovy and Ozempic, which reflects broader challenges in the competitive GLP-1 market where it is losing ground to Eli Lilly. Despite announcing a €432 million investment to expand its manufacturing capabilities in Ireland and forming a new partnership with Hims & Hers to improve patient access, the company faces a projected sales decline of up to 13% as it navigates increasing competition and pricing pressures.
“Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy and Ozempic.”
“Novo Nordisk is already a leader in weight loss. Its famous GLP-1 drug, Wegovy, is one of the best-selling medicines in this niche. And it recently launched an oral version of Wegovy.”
“Over the next few years, Novo Nordisk should expand its portfolio of approved weight loss medicines and could ride this wave well into the next decade.”
“However, the Denmark-based pharmaceutical leader depends almost entirely on its GLP-1 products (which are also approved for diabetes and other conditions) to drive top-line growth.”
“And even with its newer products, Novo Nordisk will struggle to regain its former leading position.”
“Novo Nordisk is already a leader in weight loss. Its famous GLP-1 drug, Wegovy, is one of the best-selling medicines in this niche.”
“Over the next few years, Novo Nordisk should expand its portfolio of approved weight loss medicines and could ride this wave well into the next decade.”
“However, the Denmark-based pharmaceutical leader depends almost entirely on its GLP-1 products (which are also approved for diabetes and other conditions) to drive top-line growth.”
“That's a problem, since it has lost market share to its biggest competitor, Eli Lilly, in recent years. And even with its newer products, Novo Nordisk will struggle to regain its former leading position.”
“Novo Nordisk likely has more upside potential, especially if amycretin and UBT251 ace ongoing clinical trials. But its prospects are far more dependent on the performance of its anti-obesity drugs, and if it fails to deliver, its shares will continue to plunge.”
“Investors who want to capitalize on the growing weight loss market might be tempted to turn to the current leaders in the field, Eli Lilly and Novo Nordisk. Both companies are worth serious consideration, in my view, but other drugmakers could also offer investors exposure to this area while having more diversified portfolios.”
“The Motley Fool recommends Novo Nordisk and Roche Holding AG.”
